However, some evidence suggests that DCIS with HER2-overexpressed and HR-negative may be associated with the highest rates of ipsilateral breast cancer recurrence, and future studies are needed to evaluate the possible prognostic and predictive role of HER2 in DCIS, also in residual disease after NAT [25]. This evidence concerns the gene ERBB2 and breast cancer.